SAB Biotherapeutics (SABS) Preferred Shares (2023 - 2026)

SAB Biotherapeutics has reported Preferred Shares for 4 years, with the latest figure at $59.0 in Q1 2026.

• For the quarter ending Q1 2026, Preferred Shares rose 1080.0% year-over-year to $59.0; the trailing twelve-month figure through Mar 2026 stood at $59.0 (up 1080.0% YoY), and the FY2025 full-year result was $3.0, down 40.0% from the prior year.
• Preferred Shares for Q1 2026 stood at $59.0, up from $3.0 in the prior quarter.
• The five-year high for Preferred Shares was $59.0 in Q1 2026, with the low at $3.0 in Q3 2025.
• Historically, Preferred Shares has averaged $10.0 across 4 years, with a median of $5.0 in 2023.
• Annual changes were most pronounced in 2025 — Preferred Shares plunged 40.0% — and 2026, when it surged 1080.0%.
• SAB Biotherapeutics' Preferred Shares stood at $5.0 in 2023, then changed by 0.0% to $5.0 in 2024, then sank by 40.0% to $3.0 in 2025, then soared by 1866.67% to $59.0 in 2026.
• The last three Preferred Shares figures came in at $59.0 (Q1 2026), $3.0 (Q4 2025), and $3.0 (Q3 2025), per Business Quant data.